Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

被引：1
|
作者：
Rueda, Antonio [1 ]
Calvo, Virginia [2 ]
Casanova, Maria [1 ]
Rodriguez-Abreu, Delvys [3 ]
Aguiar, David [4 ]
Llanos, Marta [5 ]
Alvarez, Ruth [6 ]
Martinez-Banaclocha, Natividad [7 ]
Alfaro, Jesus [8 ]
Quero, Cristina [9 ]
Blasco, Ana [10 ]
de la Cruz Merino, Luis [11 ]
Herrero, Joaquin [12 ]
Garcia-Arroyo, Francisco R. [13 ]
Provencio, Mariano [2 ]
机构：
[1] Hosp Costa Sol, Marbella, Spain
[2] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
[3] Hosp Insular, Las Palmas Gran Canaria, Las Palmas, Spain
[4] Hosp Dr Negrin, Las Palmas Gran Canaria, Las Palmas, Spain
[5] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[6] Hosp Virgen Salud, Toledo, Spain
[7] Hosp Gen Univ Elche, Alicante, Spain
[8] Oncologikoa, Donostia San Sebastian, Spain
[9] Hosp Univ Gen & Virgen Victoria, Malaga, Spain
[10] Hosp Gen Univ, Valencia, Spain
[11] Hosp Virgen Macarena, Seville, Spain
[12] Hosp Gen Univ Alicante, Alicante, Spain
[13] Complexo Hosp Univ Pontevedra, Pontevedra, Spain
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 06期
关键词：
NON-HODGKIN-LYMPHOMA; INDOLENT B-CELL; PLUS RITUXIMAB; MANTLE-CELL; 1ST-LINE TREATMENT; OPEN-LABEL; RELAPSED INDOLENT; MULTICENTER; OBINUTUZUMAB; THERAPY;
D O I：
10.1080/10428194.2018.1542147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1576 / 1579
页数：4
相关论文
共 50 条
  • [41] Rituximab and Bendamustine for first-line treatment of frail or elderly patients with aggressive B-cell lymphoma: first results of the German prospective phase-II BRENDA trial
    Braulke, F.
    Zettl, F.
    Ziepert, M.
    Viardot, A.
    Kahl, C.
    Prange-Krex, G.
    Korfel, A.
    Dreyling, M.
    Illmer, T.
    Birkmann, J.
    Wedding, U.
    Reichert, D.
    de Wit, M.
    Hartmann, F.
    Hurtz, H. -J.
    Poeschel, V
    Schmitz, N.
    Witzens-Harig, M.
    Klapper, W.
    Rosenwald, A.
    Wulf, G.
    Pfreundschuh, M.
    Altmann, B.
    Truemper, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 4 - 5
  • [42] Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
    Garcia-Sanz, R.
    Sureda, A.
    de la Cruz, F.
    Canales, M.
    Gonzalez, A. P.
    Pinana, J. L.
    Rodriguez, A.
    Gutierrez, A.
    Domingo-Domenech, E.
    Sanchez-Gonzalez, B.
    Rodriguez, G.
    Lopez, J.
    Moreno, M.
    Rodriguez-Salazar, M. J.
    Jimenez-Cabrera, S.
    Caballero, M. D.
    Martinez, C.
    ANNALS OF ONCOLOGY, 2019, 30 (04) : 612 - 620
  • [43] BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA. AN INTERIM REPORT OF A PHASE 2 TRIAL IN SPAIN (GELTAMO MALT-2008-01)
    Salar, A.
    Domingo, E.
    Canales, M.
    Nicolas, C.
    Panizo, C.
    Bello, J.
    Bargay, J.
    Muntanola, A.
    Rodriguez, M.
    Sancho, J.
    Caballero, D.
    Montalban, C.
    ANNALS OF ONCOLOGY, 2011, 22 : 184 - 184
  • [44] Phase II study of PEG-intron in combination with chemotherapy for the treatment of first line patients with follicular lymphoma who need to be treated. A GELA study.
    Coiffier, B
    Haioun, C
    Delaby, P
    Bauduer, F
    Salles, B
    Decaudin, D
    Mineur, P
    Peaud, PY
    Brice, P
    BLOOD, 2001, 98 (11) : 604A - 604A
  • [45] Phase II study of treatment with IPH1101 and low dose of IL-2 in combination with rituximab re-treatment in patients with follicular lymphoma
    Kunzmann, V
    Laurent, G.
    Sicard, H.
    Casasnovas, O.
    Thieblemont, C.
    de Micheaux, Lafaye S.
    Derigs, H. G.
    Chow, K. U.
    Goebeler, M.
    Einsele, H.
    Rossi, J. F.
    ONKOLOGIE, 2010, 33 : 158 - 158
  • [46] Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Reyes, Carolina
    Bernaards, Coen
    Krivasi, Tania
    Veenstra, David L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (10) : 960 - 967
  • [47] Phase II study of IPH1101 (with low dose of IL-2) in combination with rituximab re-treatment in patients with follicular lymphoma
    Casasnovas, O.
    Thieblemont, C.
    Rossi, J. F.
    Sicard, H.
    Ingoure, S.
    Audibert, F.
    de Micheaux, S. Lafaye
    Laurent, G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 560 - 560
  • [48] Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial
    Hainsworth, John D.
    Rubin, Mark S.
    Arrowsmith, Edward R.
    Khatcheressian, James
    Crane, Edward J.
    Franco, Luis A.
    CLINICAL GENITOURINARY CANCER, 2013, 11 (03) : 270 - 275
  • [49] SAFETY AND EFFICACY OF A BRIEF RITUXIMAB, BENDAMUSTINE AND MITOXANTRONE REGIMEN FOLLOWED BY RITUXIMAB CONSOLIDATION IN ELDERLY PATIENTS WITH UNTREATED ADVANCED STAGE FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PROSPECTIVE PHASE II STUDY BY FONDAZIONE ITALIANA LINFOMI
    Boccomini, C.
    Ladetto, M.
    Rigacci, L.
    Rattotti, S.
    Evangelista, A.
    Ferrero, S.
    Volpetti, S.
    Mantoan, B.
    Meli, E.
    Freilone, R.
    Corradini, P.
    Franceschetti, S.
    Rusconi, C.
    Stelitano, C.
    Dutto, F.
    Puccini, B.
    Bolis, S.
    Salvi, F.
    Fabbri, A.
    Billio, A.
    Tucci, A.
    Balzarotti, M.
    Vitolo, U.
    HAEMATOLOGICA, 2015, 100 : 19 - 19
  • [50] Pazopanib as Second Line Treatment of Platinum Sensitive SCLC Patients: A Multicenter Phase II Trial of the Hellenic Oncology Research Group
    Kotsakis, Athanasios
    Karavasilis, Vasilios
    Agelaki, Sofia
    Kentepozidis, Nikolaos
    Peroukidis, Stavros
    Samantas, Epaminontas
    Christophyllakis, Charalambos
    Dermitzaki, Eleftheria Kleio
    Koinis, Filippos
    Fountzilas, George
    Georgoulias, Vassilis
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S401 - S401
12345